BeiGene may not be a profitable business quite yet, but the Chinese biotech has two top oncology products and saw its sales soar to USD 2.2 billion in 2023. Having set its sights on markets outside of China, with its…
Poised to overtake Japan and become the world’s fourth-largest economy by 2025 according to the latest International Monetary Fund estimates and now registering heady year-on-year growth rates exceeding eight percent,…
Contributing to the September 2024 edition of DIA’s Global Forum magazine, Siva Kumar Buddha of Indegene reviews the challenges of risk communication and minimization in India’s healthcare sector. In…
A run-through of some of the most striking recent stories from pharma in the dynamic Asia-Pacific region, including Japan’s attempts to bring back Big Pharma investment; UCB’s decision to divest…
Dr Viranchi Shah of Saga Lifesciences and the Indian Drug Manufacturers Association (IDMA) outlines the Indian pharmaceutical industry’s potential for growth and its role in global health initiatives. He highlights IDMA’s focus on scaling operations, affordability, accessibility, quality, and compliance to drive positive change across the sector. Dr Shah also explains how there has been significant shift from aspirational discussions…
Drawing on a unique background in both medicine and law, Dr Milind Antani today leads the pharma and healthcare practice at Nishith Desai Associates, covering everything from regulatory work to…
Sanjay Bhutani of Bausch & Lomb outlines why the medical devices sector in India is poised for substantial growth, bolstered by increased government support and a higher healthcare budget. He…
Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year,…
India faces a significant diabetes burden, with some observers even labelling the country ‘The Diabetes Capital of the World’. Around 101.4 million adults, or 11 percent of the Indian population,…
As rare disease regulation moves from the margins to the mainstream of global health policy, India faces both a challenge and an opportunity: how to align with international best practices…
Contributing to the October 2024 edition of DIA’s Global Forum magazine, Stephanie Rosner of DIA and Martin Hodosi and Rosanna Lim of Kearney highlight the discussions from DIA’s multistakeholder Responsible…
In an era of rapid scientific breakthroughs, global regulators are navigating new challenges—accelerating approvals, harmonising standards, and integrating digital tools—while balancing safety, efficacy, and access. Throughout 2024, PharmaBoardroom spoke with…
Shagun Sharma, Vipul Kumar Gupta, and Helene Sou of Takeda, writing in the December 2024 edition of DIA’s Global Forum magazine, look at how updates to India’s regulatory framework for…
See our Cookie Privacy Policy Here
